Analysts expect Puma Biotechnology, Inc. (NASDAQ:PBYI) to report $-1.98 EPS on March, 1 after the close.They anticipate $0.06 EPS change or 2.94% from last quarter’s $-2.04 EPS. After having $-2.07 EPS previously, Puma Biotechnology, Inc.’s analysts see -4.35% EPS growth. It closed at $67.05 lastly. It is down 23.65% since February 21, 2017 and is uptrending. It has outperformed by 6.95% the S&P500.
Evoqua Water Technologies Corp (NYSE:AQUA) had a decrease of 7.87% in short interest. AQUA’s SI was 1.54M shares in February as released by FINRA. Its down 7.87% from 1.67 million shares previously. With 338,600 avg volume, 5 days are for Evoqua Water Technologies Corp (NYSE:AQUA)’s short sellers to cover AQUA’s short positions. The SI to Evoqua Water Technologies Corp’s float is 3.06%. The stock decreased 2.37% or $0.54 during the last trading session, reaching $22.2. About 229,635 shares traded. Evoqua Water Technologies Corp. (NYSE:AQUA) has 0.00% since February 21, 2017 and is . It has underperformed by 16.70% the S&P500.
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to improve cancer care. The company has market cap of $2.52 billion. The Company’s drug candidates include PB272 ) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 (neratinib (intravenous)). It currently has negative earnings. The firm also develops PB357, an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4.
Since September 6, 2017, it had 0 buys, and 6 sales for $4.70 million activity. $1.80 million worth of Puma Biotechnology, Inc. (NASDAQ:PBYI) shares were sold by BRYCE RICHARD PAUL. On Monday, January 22 Lo Steven sold $172,515 worth of Puma Biotechnology, Inc. (NASDAQ:PBYI) or 1,858 shares. Shares for $991,683 were sold by AUERBACH ALAN H on Monday, January 22. EYLER CHARLES R sold $62,117 worth of stock or 669 shares.
Investors sentiment increased to 1.55 in Q3 2017. Its up 0.34, from 1.21 in 2017Q2. It increased, as 19 investors sold Puma Biotechnology, Inc. shares while 41 reduced holdings. 41 funds opened positions while 52 raised stakes. 35.70 million shares or 3.15% more from 34.61 million shares in 2017Q2 were reported. Zurcher Kantonalbank (Zurich Cantonalbank) holds 2,559 shares. Parametric Portfolio Assoc Limited Company holds 15,028 shares or 0% of its portfolio. Renaissance Techs Lc stated it has 0.02% in Puma Biotechnology, Inc. (NASDAQ:PBYI). Federated Investors Incorporated Pa invested in 0.01% or 37,370 shares. Hsbc Public Limited reported 1,985 shares. Moreover, Hanseatic Ser has 0% invested in Puma Biotechnology, Inc. (NASDAQ:PBYI). California Employees Retirement System accumulated 108,000 shares. Sanctuary Wealth Advsrs accumulated 35,788 shares or 3.32% of the stock. Qs Invsts Limited stated it has 1,000 shares. Highlander Capital Management Ltd Liability Corp invested in 0.05% or 500 shares. Jpmorgan Chase Commerce owns 706 shares. Rock Springs Capital Management Limited Partnership reported 1.82% stake. Century holds 0.01% in Puma Biotechnology, Inc. (NASDAQ:PBYI) or 51,984 shares. The Georgia-based Invesco has invested 0% in Puma Biotechnology, Inc. (NASDAQ:PBYI). Eventide Asset Mgmt owns 0.14% invested in Puma Biotechnology, Inc. (NASDAQ:PBYI) for 20,000 shares.
EWT Holdings I Corp. provides a range of water and wastewater treatment systems and technologies, and mobile and emergency water supply solutions and services. The company has market cap of $2.51 billion. It operates through three divisions: Industrial, Municipal, and Products. It has a 196.46 P/E ratio. The Industrial segment provides capital systems and related recurring aftermarket services, parts, and consumables for treating industrial process water, utility water, and wastewater.